Company Profile
Halozyme Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- HALO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
85.76 USD (+2.60%)
Close
Last updated: August 6, 2026
7.86B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, HALO closed up 2.60% at $85.76. No new same-company headline was identified in the current news window.
Company overview
Business overview
Halozyme Therapeutics is a biopharmaceutical company best known for its enzyme technology platform that enables subcutaneous drug delivery. The business combines licensed technology revenue with development activity around oncology and other therapeutic areas.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Halozyme is a U.S.-based specialty biotech company. It sits in platform-enabled drug delivery and oncology-adjacent therapeutics.
Business Model Characteristics
The company generates value through royalty income, partner relationships, and technology licensing tied to subcutaneous formulation. Investors follow licensing growth, partner adoption, and whether the technology platform continues to expand across the industry.
Position Within the Biotechnology Landscape
Halozyme occupies a unique position in biotech because it monetizes platform technology rather than relying only on its own clinical pipeline. That makes it less binary than many development-stage peers, but still catalyst-sensitive around deal flow and partner uptake.
Future catalysts
Halozyme's catalysts are partner launches on the ENHANZE platform, especially Darzalex Faspro and VYVGART Hytrulo royalty growth, plus any new subcutaneous-drug-delivery deal. The stock moves when royalty durability and partner breadth both keep expanding.
Recent news
- 01
Halozyme Therapeutics Presents Positive Pre-Clinical Single Agent Data for PEGPH20
Source: Halozyme Therapeutics, Inc.
- 02
Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial With Second Biologic
Source: Halozyme Therapeutics, Inc.
- 03
Halozyme to Present At J.P. Morgan Healthcare Conference
Source: Halozyme Therapeutics, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Halozyme Therapeutics, Inc. (HALO)?
Halozyme Therapeutics, Inc. (HALO) most recently closed at 85.76 USD, a +2.60% move versus the previous session.
What is the market cap of Halozyme Therapeutics, Inc. (HALO)?
Halozyme Therapeutics, Inc. currently has a market capitalization of 7.86B USD on BioPharmSignal.
What does Halozyme Therapeutics, Inc. do?
Halozyme Therapeutics is a biopharmaceutical company best known for its enzyme technology platform that enables subcutaneous drug delivery. The business combines licensed technology revenue with development activity around oncology and other therapeutic areas.
On which exchange is HALO stock listed?
Halozyme Therapeutics, Inc. (HALO) is associated with NASDAQ, United States, Biopharma.
What is Halozyme?
Halozyme's catalysts are partner launches on the ENHANZE platform, especially Darzalex Faspro and VYVGART Hytrulo royalty growth, plus any new subcutaneous-drug-delivery deal.
Which conditions is Halozyme Therapeutics, Inc. targeting with Halozyme?
Halozyme Therapeutics, Inc. is associated with oncology based on its company overview and current catalyst commentary.
How does Halozyme Therapeutics, Inc. describe recent progress with Halozyme?
Halozyme's catalysts are partner launches on the ENHANZE platform, especially Darzalex Faspro and VYVGART Hytrulo royalty growth, plus any new subcutaneous-drug-delivery deal.
What is Therapeutics?
Halozyme Therapeutics is a biopharmaceutical company best known for its enzyme technology platform that enables subcutaneous drug delivery.